Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Expected To Reach $26.17 Billion By 2030 At 8.7% CAGR
The market for therapeutics utilizing ribonucleic acid (RNA) has experienced robust expansion; projections indicate a continued upward trajectory from an estimated $17.22 billion in 2025 to $18.75 billion in 2026, representing a compound annual growth rate (CAGR) of 8.9%. Factors propelling this growth during the preceding period include significant strides in molecular biology research, the promising early outcomes of RNA-targeted medications, a broadened scope in genetic disease investigation, amplified investment in pharmaceutical research and development, and a deepening comprehension of gene regulation mechanisms.
Driven by a surge in regulatory endorsements for RNA-based treatments, a heightened need for bespoke medical interventions, expanding oncology research in RNA, amplified investments in drug delivery systems, and fostering partnerships between biotechnology entities, the RNA therapeutics market is projected for substantial expansion, forecasted to reach $26.17 billion by 2030 with a compound annual growth rate (CAGR) of 8.7%. Key developments shaping this trajectory include the progressive creation of targeted RNA therapies, broader adoption of siRNA and ASO technologies, a concentrated effort on addressing rare and genetic diseases, an increase in clinical investigations for RNA-based drugs, and advancements in innovative drug delivery mechanisms.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18454&type=smp
Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Growth Factors: Which Forces Are Supporting Market Expansion?
The escalating incidence of cancer is anticipated to be a significant catalyst for the expansion of the ribose-nucleic acid (RNA)-based therapeutics market. Cancer, a disease characterized by the uncontrolled proliferation and dissemination of aberrant cells, which can prove fatal if not medically addressed, is becoming more widespread owing to factors such as an aging demographic, shifts in lifestyle habits, increased exposure to various risk factors, and advancements in diagnostic capabilities. Within this context, RNA-based therapies present a compelling approach for managing cancer by directly addressing the underlying genetic and molecular pathways of the disease. Illustratively, data from the Australian Institute of Health and Welfare indicated that approximately 151,000 cancer diagnoses (excluding skin cancers like BCC and SCC) were recorded in Australia in 2021, with projections suggesting this figure could rise to 185,000 by the year 2030, thus underscoring the influential role of rising cancer rates in stimulating growth within the RNA-based therapeutics sector.
Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Segmentation And Category Breakdown
The ribose-nucleic acid (rna)-based therapeutics market covered in this report is segmented –
1) By Type: RNA Interference (RNAi), RNA Antisense
2) By Technology: Enabling Technology, Enabled Technology
3) By Therapeutic Area: Oncology, Genetic Disorder, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Other Therapeutic Areas
4) By End User: Research Institutes, Hospitals And Clinics
Subsegments:
1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), MicroRNA (miRNA)
2) By RNA Antisense: Antisense Oligonucleotides (ASOs), Antisense RNA
Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Industry Trends: What Changes Are Reshaping Demand?
Companies at the forefront of the RNA therapeutics sector are concentrating on pioneering new drug options, including messenger RNA (mRNA) booster vaccines, aimed at elevating immunization potency, combating new viral strains, and reinforcing the long-term effectiveness of vaccine-generated immune protection. The mechanism behind an mRNA booster vaccine involves instructing cells, via messenger RNA, to produce a protein that amplifies the body’s immune defense against a specific infectious agent. As an illustration, in June 2023, Gennova Biopharmaceuticals Ltd., an Indian pharmaceutical entity, introduced GEMCOVAC-OM, which stands as India’s inaugural mRNA booster vaccine, meticulously designed to target the Omicron variant of COVID-19. This booster’s significance is underscored by the attenuated effectiveness of primary vaccines against the Omicron strain. By leveraging mRNA technology, GEMCOVAC-OM serves to augment immunological memory and provide superior defense against the mutating virus.
Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Competitive Analysis Of Major Industry Participants
Major companies operating in the ribose-nucleic acid (rna)-based therapeutics market are F Hoffmann La Roche AG, Eli Lilly And Company, Novo Nordisk AS, Regeneron Pharmaceuticals, Biogen Inc., BioNTech, Alnylam Pharmaceuticals, Sarepta Therapeutics, Ionis Pharmaceuticals, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Wave Life Sciences, Quark Pharmaceuticals, Tekmira Pharmaceuticals, ReCode Therapeutics, Arbutus Biopharma Corporation, Benitec Biopharma Inc., Olix Pharmaceuticals, Alltrna Inc., Orbital Therapeutics, Moderna Inc., CureVac NV, Silence Therapeutics plc, ProQR Therapeutics NV
Access The Complete Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Report:
Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Geographic Landscape: Which Region Dominates Industry Growth?
North Americawas the largest region in the ribose-nucleic acid (RNA)-based therapeutics market in 2025. The regions covered in the ribose-nucleic acid (rna)-based therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
